Streetbeat News

MLYS

Mineralys Therapeutics, Inc.

Industry

Biotechnology

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Open

12.27

Mkt cap

571M

Volume

221K

High

12.27

P/E Ratio

-4.16

52-wk high

16.91

Low

11.40

Div yield

N/A

52-wk low

5.85

Mineralys Therapeutics' stock (MLYS) is trading higher following Goldman Sachs' initiation of coverage with a Buy rating and a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:46 pm

Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (MLYS) with a Buy rating and a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:11 am

Mineralys Therapeutics (NASDAQ:MLYS) reported a Q4 EPS loss of $(0.61), surpassing the analyst consensus estimate of $(0.82) by 25.61%. This marks a 64.94% improvement over the $(1.74) per share loss from the same period last year.

Portfolio Pulse from dijoy@benzinga.com

March 21, 2024 | 11:03 am

Numerous companies are scheduled to report their earnings on March 21, 2024, covering a wide range of industries from technology to healthcare. The reports include a mix of expected quarterly earnings and losses, with notable companies such as Welltower, Academy Sports, Exscientia, Direxion Daily CSI China Internet Index Bull 2X Shares, and Winnebago Industries among those reporting before the bell. After the bell, companies like Lululemon Athletica, Nike, FedEx, and Intellicheck will report, providing insights into their financial health and performance.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 10:15 am

Mineralys Therapeutics (NASDAQ:MLYS) is scheduled to release its quarterly earnings report on March 21, 2024, with an expected EPS of $-0.82. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat resulting in a 6.74% drop. Shares are currently trading at $13.48, down 13.18% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 3:01 pm

Compass Minerals International, Inc. (CMP) shares fell by 9% following disappointing quarterly results, missing both earnings and sales estimates. Other stocks showed significant movement, with notable gainers including Syra Health Corp. (SYRA) and Hitek Global Inc. (HKIT), and losers like Tenax Therapeutics, Inc. (TENX) and Bakkt Holdings, Inc. (BKKT). The article also highlights stocks that surged due to partnerships, financial results, and other corporate announcements.

Portfolio Pulse from Avi Kapoor

February 08, 2024 | 6:07 pm

Mineralys Therapeutics shares surged following the announcement of securing $120 million in private placement financing. This significant financial infusion is expected to bolster the company's operations and potentially accelerate its drug development programs.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 5:29 pm

Arm Holdings reported better-than-expected Q3 results, leading to a 47.3% surge in its shares. Other companies like Oscar Health, Mineralys Therapeutics, and Viking Therapeutics also saw significant gains following positive financial results or announcements. Companies such as Monolithic Power Systems, Ralph Lauren, and Advanced Drainage Systems reported strong earnings, raising guidance and dividends. Disney announced a $1.5 billion investment in Epic Games and a new share repurchase program. Overall, several stocks recorded gains in Thursday's session.

Portfolio Pulse from Avi Kapoor

February 08, 2024 | 3:24 pm

Mineralys Therapeutics has announced a significant financial move with a $120 million private placement financing. This influx of capital is aimed at supporting the company's ongoing and future projects, potentially accelerating its research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 1:14 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. China SXT Pharmaceuticals, Titan Pharma, Trxade Health, Elicio Therapeutics, Nutex Health, and Mineralys Therapeutics were among the gainers with notable percentage increases in their stock prices. Conversely, Jin Medical International, Tenax Therapeutics, InVivo Therapeutics Holdings, HOOKIPA Pharma, ThermoGenesis Holdings, and Exicure were the losers, experiencing substantial declines.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.